3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
413
Lymphoma
401
Lymphoma, Non-Hodgkin
337
Leukemia, Lymphocytic, Chronic, B-Cell
302
Lymphoma, Follicular
295
Lymphoma, Mantle-Cell
225
Lymphoma, B-Cell, Marginal Zone
159
Leukemia
119
Lymphoma, B-Cell
112
Burkitt Lymphoma
110
Waldenstrom Macroglobulinemia
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
90
Recurrence
83
Hodgkin Disease
60
Lymphoma, Large-Cell, Immunoblastic
57
Neoplasms
39
Multiple Myeloma
26
Lymphoma, Large-Cell, Anaplastic
26
Myelodysplastic Syndromes
25
Leukemia, Myeloid, Acute
24
Dendritic Cell Sarcoma, Interdigitating
22
Hematologic Neoplasms
21
Leukemia, Hairy Cell
20
Intraocular Lymphoma
17
Leukemia, Prolymphocytic
16
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, T-Cell
14
Neoplasms, Plasma Cell
13
Lymphoproliferative Disorders
12
Hematologic Diseases
12
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Oncology Patients Receiving Chemotherapy
×
Rituximab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts